Business briefs: Takeda, Stryker

Share this article:

Takeda scored an approvals hat-trick Friday with the FDA's Friday approval of the active ingredient alogliptin (AKA Nesina) as a stand-alone treatment for type 2 diabetes—as well as alogliptin-metformin combination Kazano and alogliptin-pioglitazone combo Oseni.

Stryker is solidifying its Asian footprint. The Michigan device maker announced this month that it is buying out Asia-based Trauson Holdings for $764 million in cash. The firms have been working together since 2007. “The acquisition of Trauson is a critical step toward broadening our presence in China and developing a value segment platform for the emerging markets,” Stryker President and CEO Kevin Lobo said in a statement. The announcement also noted that Trauson is a major competitor. The deal is expected to close by the end of the second quarter.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.